• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Expansion

HBM leads €41m round for AAA

  • Ellie Pullen
  • 18 February 2014
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

HBM Healthcare Investments has led a €41m funding round for Advanced Accelerator Applications (AAA), a French biopharma company specialising in molecular nuclear medicine.

HBM contributed €20m to the round.

Several existing investors also took part in the round, including Tamburi Investment Partners. The company has been previously backed by Seventure Partners. According to AAA, it has a total of 155 private and institutional investors.

Advanced Accelerator Applications

  • DEAL:

    Expansion

  • VALUE:

    €41m

  • LOCATION:

    Saint-Genis-Pouilly

  • SECTOR:

    Biotechnology

  • FOUNDED:

    2002

  • TURNOVER:

    €56.6m

  • EBITDA:

    €14m

  • STAFF:

    280

The capital increase will allow AAA to accelerate its internationalisation efforts, with a particular focus on bolstering its presence in the US. The company will also use the funds to finance the development of its portfolio of molecular nuclear medicine (MNM) products.

Previous funding
The company raised €4.8m in a funding round in May last year, with participation from Seventure. The round valued AAA at approximately €265m, according to the company.

In July 2011, AAA secured €40m from a consortium of new and existing investors.

Company
AAA is headquartered in Saint-Genis-Pouilly, with a total of 17 production facilities across 10 countries including Italy, Germany, Switzerland, Spain, Poland and Portugal. The company is expecting to report a turnover of €56.6m for 2013, representing a 27% increase on 2012, as well as an EBITDA of €14m - a 49% increase on the previous year.

The company specialises in MNM, with a focus on molecular imaging and personalised medicine (therapy for personalised treatment of serious diseases). MNM is a medical technique that uses trace amounts of radiopharmaceuticals, which are injected into a patient's body, to create images of organs and lesions, as well as treating diseases such as cancer.

AAA is also the developer of positron emission tomography (PET) radiopharmaceuticals, which are predominantly used in clinical oncology, neurology and cardiology.

The company was founded in 2002 as a spinout from the Geneva-based European Organisation of Nuclear Research. It currently employs 280 staff.

People
Stefano Buono is the CEO of AAA. HBM CEO Andreas Wicki will join the company's board of directors following the funding round.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Expansion
  • France
  • Healthcare
  • France
  • Seventure (SPEF)

More on Expansion

Wealth managers and financial advisers
Blackstone takes minority stake in Groupe Premium

Deal values French wealth manager at EUR 1.15bn after earlier full exit attempt saw Eurazeo target EUR 1.5bn

  • Expansion
  • 31 July 2023
Risk and compliance management services
e-Attestations aims to triple size with new Keensight backing

Keensight is investing in the risk management platform via its EUR 1bn fifth fund, which closed in 2019

  • Expansion
  • 25 July 2023
Bolt-ons and buy-and-build platforms
The Bolt-Ons Digest - 3 July 2023

Unquote’s selection of the latest add-ons with Palatine's Anthesis, Nordic Capital's Regnology, Waterland's Janssen and more

  • Expansion
  • 03 July 2023
Valentina Vitali of Limerston Capital
GP Profile: Limerston Capital anticipates higher volume but more complex M&A as market steadies

UK-based GP is seeing dealflow driven by carve-outs and buy-and-build in a market where organic multiple arbitrage is no longer a given

  • GPs
  • 07 June 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013